Latest Morphotek Inc. Stories
SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.